November 26, 2009Journal of Applied Physiology
The 2009 Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management
Population
Patients with cardiovascular diseases including heart failure, essential hypertension, postural circulatory…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports expanded sympathetic-targeted therapies beyond heart failure; leaves open optimal use of renal denervation in hypertension.
Key Points
- This review aims to explore the abnormalities of the sympathetic nervous system and their impact on cardiovascular diseases.
- Assessment of sympathetic activity using postganglionic sympathetic efferents recordings and norepinephrine spillover measurements.
- Analysis of the role of sympathetic nervous system in heart failure, essential hypertension, postural circulatory control disorders, and psychogenic heart disease.
- Review of clinical translations from pathophysiology to medical management across different cardiovascular conditions.
- Sympathetic nervous system abnormalities contribute significantly to heart failure, hypertension, and psychogenic heart disease.
- Established treatments include beta-adrenergic blockers for heart failure, showing effective clinical translation.
- Recent advances in renal sympathetic nerve ablation provide promising prospects for resistant hypertension.
Structured PICO
P
Population
Patients with cardiovascular diseases including heart failure, essential hypertension, postural circulatory control disorders, and psychogenic heart disease
I
Intervention
Medical management targeting the sympathetic nervous system (e.g., beta-adrenergic blockers, catheter-based renal sympathetic nerve ablation)
This review highlights the critical role of sympathetic nervous system pathophysiology in cardiovascular diseases and the ongoing transition of this knowledge into targeted medical therapies.
Cite This Study
Murray Esler (2009) studied this question.